First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety, tolerability, pharmacokinetics, pharmacodynamic...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Aurélien Marabelle, Aung Naing, Funda Meric-Bernstam, Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMJ Publishing Group 2020-05-01
Cyfres:	Journal for ImmunoTherapy of Cancer
Mynediad Ar-lein:	https://jitc.bmj.com/content/8/1/e000222.full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!